ASG-15ME is a Study of Escalating Doses of AGS15E Given as Monotherapy in Subjects With Metastatic Urothelial Cancer

NCT01963052 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

93

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Urothelial Cancer

Interventions

DRUG: AGS15E

Sponsor

Astellas Pharma Global Development, Inc.

Collaborators

[object Object]